Media ReleasesAntisense Therapeutics

View All Antisense Therapeutics News


Antisense Therapeutics Limited (ASX:ANP) ATL1101 for Prostate Cancer Update

ATL1101 for Prostate Cancer Update
 
As previously reported, Antisense Therapeutics Limited (ANP) is seeking to partner the further development of its second generation antisense compound - ATL1101 for prostate cancer. This follows successful animal studies where ATL1101 was shown to suppress human prostate tumour growth. These studies were conducted as part of a collaborative research program with leading prostate cancer researcher, Professor Martin Gleave at the Vancouver Prostate Cancer Centre.
 
As part of ANP’s strategy to partner ATL1101 and as previously reported, ANP had supplied ATL1101 drug product to a specialist oncology company for the purpose of evaluating the compound in their animal models of cancer. The Company evaluated ATL1101 in a different (non prostate) tumour system and determined not to proceed with further experimental work on ATL1101.
 
This specific outcome does not affect ANP’s partnering plans for the further development of ATL1101 as a treatment for prostate cancer as there is limited experience with the use of second generation antisense drugs in the non prostate tumour system used in this case in comparison to the prostate cancer models employed by Professor Gleave’s research group. Professor Gleave’s group also conducted preclinical research on another 2nd generation antisense drug developed by OncoGenex Pharmaceuticals Inc. which has since successfully completed Phase II trials in a range of cancers including prostate and is now in Phase III clinical trials for prostate cancer.
 
Given Professor Gleave’s successful studies specifically related to the prostate cancer application of ATL1101, ANP will continue to seek a development partner primarily for this indication. ANP is in discussions with other parties interested in the development of ATL1101 for prostate cancer.
 
ANP has patent protection for ATL1101 to 2024, extendable up to 2029 in the US, Australia, Europe and Japan.
Download this document